Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
agriculTurE wAste PyrOlysis and Thermocomposting for renewable energy in Sustainable agri-food sector (TEAPOTS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Innovation actions
Countries involved: Italy,Portugal,Greece,Germany,Netherlands,Denmark,Czechia
Call: Renewable energy incorporation in agriculture and forestry (HORIZON-CL5-2022-D3-02, 2022)
Start date: 2024-01-01
End date: 2027-12-31
Duration (months): 48.0
Total project cost (EUR): 8185563.57
EU funding (EUR): 7027319.13
Participants: 18
Project status: SIGNED

TEAPOTS aims to give agri-food players an innovative integrated, modular, and flexible solution to meet local and seasonal energy demand through the valorisation of lignocellulosic and difficult to be treated agricultural waste while producing biochar. The first valorisation process will employ pyrolysis to extract heat from waste. Heat will be employed by an Organic Rankine Cycle to produce electric energy, which will be employed by a Dry Cooler & Oil-free AWC to cool down cold rooms for storing agri-food products. The second process will extract heat using a Compost Heat Recovery System to harness hot water from the oxidation of biomass while producing compost. Heat will be used to provide sanitary hot water. These technologies will be integrated in the TEAPOTS Integrated Solution, TIS, to demonstrate the feasibility of the entire process using all the modules to provide refrigeration. Biochar and compost will be used as plant biostimulants to increase yields and store carbon in soil improving the environmental footprint of the end-user. Feedstocks to be used in the TIS will be mixed to improve energy production and products’ quality. Field and satellite data will be gathered to evaluate biomass growth, while the TIS operational data will be used to evaluate the environmental impact, through LCA analysis, and the overall functionality of the solution. Data will be integrated in a database which will allow the prediction of waste biomass production. This will be used by a Data Driven Decision Support System (DSS) to improve field and waste logistics, which will provide the means to keep the TIS up and running. The prediction system and the DSS will be integrated in the TEAPOTS Digital Platform, which will have an easy-to-use user interface to help end-users in the management of the entire solution. A Multy-Actor Approach will be employed to create a network of biomass producers interested in using agricultural waste to improve their environmental impact

Keywords: carbon neutral,waste,seasonal demand,valorisation,biochar,compost,circular economy,multy actor approach,network,farmers,food,data,agriculture,yields
A Microscale View to Coral Function in a Changing Environment (MicroCoFE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Denmark,Germany
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-11-01
End date: 2025-10-31
Duration (months): 24.0
Total project cost (EUR): 214934.4
EU funding (EUR): 214934.4
Participants: 2
Project status: SIGNED

Tropical reef-building corals live in a dynamic environment with fluctuating exposure to solar light and seawater flow. It has long been assumed that corals interact passively with the surrounding seawater via a so-called diffusive boundary layer (DBL), which is a thin (~0.1-1 mm) layer of water located at the immediate surface of the coral, wherein molecular diffusion is the dominant transport mechanism for gases and solutes. The DBL can thus be an important regulating mechanism for coral metabolism. However, the recent discovery that some corals possess the ability to enhance mass transport across and within the DBL via the generation of vortices caused by the beating of epidermal cilia indicates a more complex and active control of mass transfer, albeit the importance for coral ecophysiology and stress responses remains unexplored. In this project, I will: i) develop and apply novel imaging approaches (using optical sensor nanoparticles for oxygen and pH in combination with a particle imaging velocimetry system) for studying flow and mass transfer at the coral-seawater interface; and ii) use the novel imaging techniques together with other microenvironmental sensing approaches (microsensors and optical coherence tomography) to study how ciliary beating affects coral ecophysiology. This will generate novel insights to fundamental questions of how corals exchange solutes with the surrounding seawater, how these basic processes are affected by environmental perturbations (of e.g. temperature, oxygen level and pH), and the relationship between these external processes and the internal structural heterogeneities of the coral tissue. The project will be conducted at the Marine Biology Section of the University of Copenhagen, where all experiments will take place under the supervision of Prof. Dr. Michael Kühl and complemented by a secondment at the Max Planck Institute for Marine Microbiology (Germany) and a short visit to the Graz University of Technology (Austria).

Keywords: coral,flow,ecophysiology
KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS (RAS-AlphaTAC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Belgium
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2023-POC, 2023)
Start date: 2023-08-01
End date: 2025-01-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

The RAS pathway is the most frequently activated signaling node in human cancer. Activating KRAS mutations are found in approximately one in seven human cancers. KRAS signaling is also activated in a significant subset of human cancers that lack KRAS mutations. Targeting KRAS has been a central goal during the past four decades, and the efforts have intensified over the past years, ignited by the approval of the KRAS-G12C inhibitors. A targeted KRAS degradation approach is an attractive solution for blocking KRAS activity, and within the Ub-RASDisease project, we explored the degradability of wild-type and mutant KRAS proteins. In parallel, my group initiated studies to combine the Alphabody technology with the targeted protein degradation approach by designing an AlphaTAC as a novel therapeutic modality. The goal of this project is to generate and pre-clinically validate AlphaTACs targeting KRAS for degradation. This will strengthen the Proof of concept on the AlphaTAC utility in targeted protein degradation and provide support for establishing a proprietary platform in view of the creation of a new spin-off company.
Neuroscience in the real world: Representation of position, direction and environmental borders in the hippocampal formation of bats navigating outdoors on a remote oceanic island (NEURO_OUTDOORS)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing , nervous system  function and dysfunction , systems neuroscience  and modelling , biological basis of cognitive processes and of behaviour, neurological and mental disorders – In humans and all other organisms
Countries involved: Israel
Call: ERC ADVANCED GRANTS (ERC-2024-ADG, 2024)
Start date: 2025-08-01
End date: 2030-07-31
Duration (months): 60.0
Total project cost (EUR): 3124999.0
EU funding (EUR): 3124999.0
Participants: 1
Project status: SIGNED

Navigation is a key behavior, studied by multiple research fields. In ethology, wild animals are tracked outdoors using GPS tags as they navigate hundreds of meters or kilometers. In neuroscience, experiments are very different: laboratory animals are tracked inside small ~1×1-meter boxes, while recording the activity of navigation-related neurons – such as place cells, grid cells, head-direction cells, and border cells. However, it is unknown whether these spatial neurons, as studied in small laboratory-sized environments over 50 years, are relevant to large-scale navigation in the real world – outdoors. In this proposal we will address this major gap, by conducting the first ever neural recordings from the brain’s “navigation circuit” in animals navigating outdoors. We will implant bats with tetrode microdrives, and will release them to fly on a remote, uninhabited oceanic island. Using custom wireless neural-logger and GPS, we will study the neurobiology of navigation – for the first time – in the real world. We will explore: (1) How place cells and grid cells represent large natural habitats outdoors? (2) How these neurons encode 3D space – and in particular, altitude – in an open environment without a ceiling? (3) Are there border cells in animals navigating outdoors – e.g. border cells encoding the land/sea border, which is the “end of the world” for the bat? (4) Do head-direction cells represent a geographical compass? Specifically: do they maintain their head-direction tuning across all geographical locations on the island, and irrespective of moon movements? Preliminary experiments that we conducted on Latham Island, Tanzania, showed the feasibility of this project. We will record the same neurons outdoors and indoors, in a flight-tent on the island. This research will revolutionize the neurobiology of navigation – and it will be the first neurophysiological study, in any mammalian species and any brain region, of Neuroscience in the real world.

Keywords: place cells,head direction cells,grid cells,border cells,boundary cells,hippocampus,hippocampal formation,entorhinal cortex,neurophysiology,spatial cognition,navigation,bats
Catalytic Atroposelective Synthesis for Revealing Elusive Bioactive Conformations and Shapes (AtropShape)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure -properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Czechia
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 1499041.0
EU funding (EUR): 1499041.0
Participants: 1
Project status: SIGNED

Atropisomeric molecules (atropisomers) are separable conformational isomers arising from restricted rotation around a single bond. Atropisomers have revolutionized the treatment of several deadly diseases. The principal goal of AtropShape is to create pharmaceutical leads with unusual conformations and shapes by developing catalytic stereoselective (atroposelective) synthesis methods toward difficult-to-access drug-like atropisomers. Because atropisomers are chiral, they give rise to two or more isomers that have different pharmacological properties. These attributes relate to a crucial, yet minimally investigated and poorly understood fundamental question of how conformational changes, from achiral and relatively planar to chiral and more tridimensional atropisomeric forms, impact a molecule’s ability to interact with biological receptors. But to study such range of atropisomers and related concepts, one must first of all create them. Therefore, I will introduce three new catalytic atroposelective methods. (1) We will develop unprecedented atroposelective amide-bond formations and apply them to synthesis of the first examples of peptidomimetics with an atropisomeric amide moiety. (2) We will efficiently generate, by alkyne cyclization strategies, sphere-shaped atropisomers. This rarely investigated area of molecular shape is much sought-after in drug discovery. (3) We will introduce the first instances of atroposelective decarboxylation of esters. The proposed methods will offer direct access to an assortment of bioactive atropisomers, which will be easily modifiable to generate, by diversity-oriented synthesis approaches, libraries of drug-like molecules which will be tested broadly in medicinal chemistry. Collectively, the resulting knowledge will shed light on key differences between pharmacological properties of achiral compounds and chiral atropisomeric molecules, constituting an invaluable insight for drug discovery and development.
Enabling the next generation in search of blood cancer cures (CarrerasPathfinders)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Co-funding of regional, national and international programmes
Action type: Marie Skłodowska-Curie actions
Countries involved: Spain,United States,Netherlands,Germany,Italy,United Arab Emirates,Switzerland,United Kingdom,Norway,Belgium,Slovenia,Slovakia,Bulgaria,Czechia,Hungary,Cyprus,Romania,Portugal
Call: MSCA COFUND 2022 (HORIZON-MSCA-2022-COFUND-01, 2022)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 1881600.0
EU funding (EUR): 1881600.0
Participants: 48
Project status: SIGNED

The CarrerasPathfinder program is new a world-wide unique doctoral program that covers the entire spectrum of research and innovation in blood cancers from understanding disease biology to the implementation of novel processes in the clinical practice. The program will fund 14 excellent Doctoral Candidates (DCs) for a period of 48 months. DCs will perform collaborative PhD projects involving associated partners from different sectors, countries, and disciplines through secondments. DCs will improve their research capacity and transferable skills through high-quality supervision arrangements and a tailored training program. The program has been designed and will be hosted by the Josep Carreras Leukaemia Research Institute (IJC) which is the first European non-profit institute exclusively devoted to blood cancers. By answering the European needs for human resources, it is fully aligned with the 13 recommendations of the EU Cancer Board’s Draft Mission and the Europe’s Beating Cancer Plan (2021). The CarrerasPathfinder program has a strong triple-I dimension of internationality, inter-sectorality and interdisciplinarity in training, networking, co-supervision and research. Its specific objectives are: • To develop an excellent doctoral program in blood cancer research conceived as a pilot for a permanent international doctoral program • To equip DCs with a unique skill set boosting effectiveness and innovation capacity. • To promote DCs’ career development and increase their employability in different sectors. • To establish the IJC as a European reference for research and training in blood cancers. • To provide Europe with a new generation of researchers able to address unmet needs and societal challenges of blood cancers. • To contribute to structuring the European research area by collaborating and synergizing with other European key opinion leaders.

Keywords: leukeamia,blood diseases,patients engagement,international,phd fellow,scientific skills,transferable skills,leadership,mobility,international,basic and translational research
Cognitive Robotics for Healthcare (RoBee M1)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Italy
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

An ageing population and shortage of skilled labour are pressing challenges in many countries. More and more people require stationary care, day care, and rehabilitation, while less and less personnel is available to provide these services. Oversonic is developing and testing a cognitive, humanoid robot, RoBee M1, capable of providing assistance in healthcare and of alleviating healthcare professionals from repetitive tasks, freeing them up for the important aspects of their jobs. The robot can interact naturally with patients and healthcare personnel using natural language or gestures. It can assist in daily tasks, perform rehabilitation exercises with the patient, accompany the patient to meals or appointments, and interact socially and empathetically with the patient. The payback period for the healthcare provider is between one year in 24/7 operation and three years in single-shift operation. The robot is based on our existing product RoBee for industrial applications, the first humanoid robot that is fully CE compliant and certified to safely cooperate with humans without external safety measures. RoBee is a mature (TRL 9) product that assists our industrial customers in assembly, machine tending, packing, or logistics. The healthcare robot RoBee M1 is currently at TRL 6 as initial field testing is performed at a hospital and a daycare centre. Oversonic was founded in 2020 and today has 65 employees. It is on a strong growth trajectory, expecting to sell 980 robots per year by 2026 and over 6,500 units per year by 2028. In healthcare, we plan to sell 200 RoBee M1 units per year by 2028. Additional, recurring revenues will be generated from services. We target a revenue of €810m and an EBITDA of €310m by 2028.

Keywords: humanoid robotics,cognitive robotics,healthcare,neuro rehabilitation
New Users for a Better ICOS (NUBICOS)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: Development and infrastructures
Action type: Research and Innovation actions
Countries involved: Finland,Sweden,Germany,Italy,Norway,Belgium,France,Ireland,United Kingdom
Call: Consolidation of the RI landscape – Individual support for evolution and long-term sustainability of pan-European research infrastructures (HORIZON-INFRA-2023-DEV-01, 2023)
Start date: 2024-01-01
End date: 2027-12-31
Duration (months): 48.0
Total project cost (EUR): 4999490.0
EU funding (EUR): 3999592.0
Participants: 14
Project status: SIGNED

The Integrated Carbon Observation System (ICOS) is a fully operational European Landmark research infrastructure providing standardised high-precision observations on greenhouse gases and their fluxes. The ICOS infrastructure is currently covering 16 countries with 170 stations. In this project, we will work with new users for ICOS data from satellite and modeling communities and prepare products for policymakers. We are improving sustainability of ICOS by streamlining the data pipelines and strengthening the community engagement including new members. In addition to data, ICOS is producing protocols and processes, which are now needed for the global greenhouse gases (GHG) initiative coordinated by World Meteorological Organization (WMO), thus strengthening the European leadership in it. NUBICOS will focus on four specific objectives: 1. The cooperation between ICOS and the remote sensing community will be deepened. 2. The value chain from observations to climate services will be improved. 3. The internal engagement of ICOS and the identity of the ICOS community will be strengthened. 4. The global cooperation of ICOS, particularly in the WMO framework, will be intensified.

Keywords: remote sensing community,strengthened integrated carbon observation system,data observations value chain,internal and global cooperation,climate services,greenhouse gases
Bringing MYC inhibition to the brain by ultrasound technology (SonoMYC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2025-POC, 2025)
Start date: 2025-10-01
End date: 2027-03-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

Brain tumours and brain metastases pose a significant therapeutic challenge due to limited treatment options, fatally linked to high morbidity and mortality. Treatment of these cancers is hindered by the presence of the blood-brain barrier (BBB), that restricts the free passage of molecules larger than 400 daltons, reducing the effectiveness of therapeutically impermeable compounds. While deregulation of the MYC oncogene is a main feature of these cancers, to date, effective and clinically-viable, BBB-permeable MYC inhibitors are lacking. This project proposes to combine Omomyc (OMO-103), developed in our laboratory and the best characterized, direct MYC inhibitor, with Carthera's SonoCloud technology, which temporarily disrupts the BBB using ultrasound. Omomyc is currently under clinical evaluation for other systemic aggressive cancers, under the sponsorship of Peptomyc, a spin-off from our lab, focusing on clinical application of our inhibitors. This new investigation will establish the feasibility and viability of its commercial development into a disruptive novel treatment for primary and metastatic brain tumours. This combination aims to enhance OMO-103 delivery to the brain, to improve its therapeutic efficacy and reducing any potential systemic side effects. The synergy between these technologies has the potential to generate new intellectual properties, facilitate technology transfers, and address a growing market for brain tumour therapies. By overcoming the BBB challenge and directly targeting MYC, this approach could significantly impact brain cancer treatment and create new commercial opportunities.